Publicacións nas que colabora con Xavier Montalbán Gairín (62)

2023

  1. A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patients

    Multiple Sclerosis Journal

  2. Assessment of Upper Extremity Function in Multiple Sclerosis: Feasibility of a Digital Pinching Test

    JMIR Formative Research, Vol. 7

  3. Association of Early Progression Independent of Relapse Activity with Long-term Disability after a First Demyelinating Event in Multiple Sclerosis

    JAMA Neurology, Vol. 80, Núm. 2, pp. 151-160

  4. Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating Event

    Neurology, Vol. 101, Núm. 13, pp. E1280-E1292

  5. Association of magnetic resonance imaging phenotypes and serum biomarker levels with treatment response and long-term disease outcomes in multiple sclerosis patients

    European Journal of Neurology

  6. Deciphering multiple sclerosis disability with deep learning attention maps on clinical MRI

    NeuroImage: Clinical, Vol. 38

  7. Diagnostic challenge in children with an acquired demyelinating syndrome: an illustrative case report

    Frontiers in Neuroscience, Vol. 17

  8. Fármacos modificadores de la enfermedad en la esclerosis múltiple durante la lactancia: revisión de la evidencia actual

    Revista de neurologia, Vol. 76, Núm. 1, pp. 21-30

  9. Global and Regional Deep Learning Models for Multiple Sclerosis Stratification From MRI

    Journal of Magnetic Resonance Imaging

  10. Locus for severity implicates CNS resilience in progression of multiple sclerosis

    Nature

  11. Myelin Oligodendrocyte Glycoprotein Antibodies in Adults with a First Demyelinating Event Suggestive of Multiple Sclerosis

    Annals of Neurology

  12. Neural correlates of digital measures shown by structural MRI: a post-hoc analysis of a smartphone-based remote assessment feasibility study in multiple sclerosis

    Journal of Neurology, Vol. 270, Núm. 3, pp. 1624-1636

  13. Teriflunomide and Epstein–Barr virus in a Spanish multiple sclerosis cohort: in vivo antiviral activity and clinical response

    Frontiers in Immunology, Vol. 14

2022

  1. A smartphone sensor-based digital outcome assessment of multiple sclerosis

    Multiple Sclerosis Journal, Vol. 28, Núm. 4, pp. 654-664

  2. Correction to: Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre (Journal of Neurology, (2022), 269, 4, (1764-1772), 10.1007/s00415-021-10958-z)

    Journal of Neurology

  3. Correction to: Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing–remitting multiple sclerosis patients (Journal of Neurology, (2022), 269, 1, (452-459), 10.1007/s00415-021-10823-z)

    Journal of Neurology

  4. Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the ANKRD55–IL6ST Gene Region in Immature Dendritic Cells

    Frontiers in Immunology, Vol. 12

  5. Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis

    Neurology(R) neuroimmunology & neuroinflammation, Vol. 9, Núm. 2

  6. Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre

    Journal of Neurology, Vol. 269, Núm. 4, pp. 1764-1772

  7. Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?

    Multiple Sclerosis Journal, Vol. 28, Núm. 7, pp. 1138-1145